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is more costly than BSC, it is more effective. Using the US
$50,000/QALY incremental cost-effectiveness threshold, suni-
tinib seems to be cost-effective in the second-line treatment of
mRCC in Argentina.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a pro-
gressive disease that is associated with signiﬁcant health and 
economic burden. Although durable response from current 
treatments such as imatinib is achievable for many patients, a
subset of patients develop resistant disease. This study aims to
predict the impact of short-term response upon the cost-
effectiveness of new interventions to treat CML. METHODS: A
Markov model was developed to estimate the non-drug costs and
health outcomes associated with treatments for chronic phase
CML. Two hypothetical treatment options were modelled, each
with a different short-term best response proﬁle. Short-term
response was deﬁned as “no response” (NR), “complete haema-
tological response” (CHR), partial cytogenetic response (PCR)
and complete cytogenetic response (CCR). Patients progressed
through the stages of the disease at different rates, based on their
short-term best response to treatment. Unit costs were drawn
from national databases, and were factored according to
resource use to estimate total costs. Because the purpose of this
study is to inform the cost-effectiveness of novel treatments, drug
costs are not included in the model. Resource use and quality-
adjusted life year (QALY) scores were stratiﬁed according to the
patient’s current health status and response level. RESULTS:
Patients who achieve no response are estimated to experience a
total of 1.48 QALYs and incur costs of £39,724 over their life-
time. Those who achieve CHR, PCR and CCR experience 5.11,
9.73 and 10.00 QALYs, and costs of £55,816, £65,610 and
£66,562 respectively. CONCLUSION: Short-term response is
related both to long-term survival and increased costs. The
increased costs associated with improved response are a result of
the patient’s improved survival and consequent increased
resource use. However, these costs may be offset by reductions
in major cost drivers such as hospitalisation and/or other
resource use as a result of the improved response.
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OBJECTIVES: Anemia is commonly experienced by cancer
patients receiving chemotherapy. Two erythropoietic agents have
been FDA-approved for ﬁxed dosing in patients with chemother-
apy-induced anemia (CIA) [epoetin alfa (EPO) 40,000 Units QW,
darbepoetin alfa (DARB) 500 mcg Q3W]. The current analysis
was conducted to compare medical costs between approved EPO
and DARB dosages based on clinical data from two 16-week,
randomized, controlled trials (Canon JNCI 2006, Waltzman
Oncologist 2005). METHODS: A cost-minimization analysis
was utilized to compare direct medical costs (drug acquisition
and visit costs) of treating patients with EPO QW versus DARB
Q3W. Drug cost was based on December 2006 U.S. wholesale
acquisition cost (EPO $12.52/1000 Units; DARB $4.446/mcg).
Visit cost was calculated based on physician ofﬁce visit and injec-
tion cost ($53.27). Sensitivity analyses were conducted on drug
cost, physician visit cost, hemoglobin monitoring, and transfu-
sion requirements. RESULTS: Results from the base case sce-
nario showed that direct medical costs of treating patients with
DARB Q3W was $1595 more expensive (28% cost premium)
than treating patients with EPO QW ($5795 for EPO QW vs.
$7390 for DARB Q3W). Drug cost represented °Y´90% of total
direct medical costs in both groups (EPO : drug cost $5239, visit
cost $555; DARB : drug cost $7149, visit cost $240). Sensitivity
analyses revealed the cost premium associated with DARB Q3W
therapy to be between 13% and 42%, indicating that direct
medical cost of EPO QW therapy was consistently lower than
that of DARB Q3W. CONCLUSION: This economic analysis
demonstrated that direct medical costs for DARB Q3W therapy
was consistently higher than EPO QW, with cost premiums asso-
ciated with DARB Q3W ranging from 13%–42%. Drug cost was
the major driver of total direct medical cost in both groups.
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OBJECTIVES: Malignant metastatic melanoma (MMM), the
most serious form of skin cancer, currently accounts for 79% of
all skin cancer deaths, and is becoming increasingly common.
MMM patients have limited treatment options and low survival
rates. The ﬁve-year survival rate for patients with regional
melanoma is 63.8%, compared to 16.0% for patients with
metastatic melanoma. Despite the importance of this cancer, data
on its economic burden are limited. METHODS: A prevalence-
based model was developed to estimate the aggregate annual cost
burden attributable to MMM from a societal perspective, includ-
ing costs of medical treatment and lost productivity in the US.
Key relationships represented in the model include the annual
numbers of patients treated for MMM by age group; utilization
of cancer-speciﬁc treatments; unit costs of these treatments; work
days missed by these patients; and wage rates. Data sources
included the linked Surveillance, Epidemiology and End Results
(SEER)–Medicare database, the Bureau of Labor Statistics, and
published literature. RESULTS: The annual prevalence of MMM
in the US was estimated to be 5778 cases. The associated annual
cost burden was estimated at approximately $202 million
($34,991 per patient) in 2005. Health care costs and lost pro-
ductivity accounted for 87.1% ($176 million) and 12.9% ($26
million) of the total burden, respectively. The principal cost
driver was cancer-related hospitalization (accounting for 31.4%
of total health care costs) for procedures including lym-
phadenectomy, radiofrequency ablation, chemotherapy, and
arterial embolization. SNF services, hospice care, physician ser-
vices and outpatient hospital services accounted for 5.8%, 5.9%,
11.6% and 8.0% of health care costs, respectively. Sensitivity
analyses varying assumptions regarding health care utilization
and wage rates resulted in a range in the estimated annual burden
from $207 to $216 million. CONCLUSION: The economic
burden of MMM in the US is substantial. New therapies for
MMM have the potential to yield considerable economic bene-
ﬁts to society.
